证券代码：002370 证券简称：亚太药业 公告编号：2025-064 浙江亚太药业股份有限公司 关于股票交易异常波动公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况 浙江亚太药业股份有限公司（以下简称"亚太药业"或"公司"） 股票（证券简称：亚太药业，证券代码：002370）于 2025 年 7 月 25 日、2025 年 7 月 28 日、2025 年 7 月 29 日连续三个交易日收盘价格 涨幅偏离值累计超过 20％，根据深圳证券交易所的有关规定，属于股 票交易异常波动的情况。 二、公司关注并核实情况说明 针对公司股票异常波动，公司就有关事项进行了核实，现将有关 情况说明如下： 三、不存在应披露而未披露信息的说明 本公司董事会确认，本公司目前没有任何根据《深圳证券交易所 股票上市规则》等有关规定应予以披露而未披露的事项；董事会也未 获悉公司有根据《深圳证券交易所股票上市规则》等有关规定应予以 披露而未披露的、对公司股票及其衍生品种交易价格产生较大影响的 信息；公司前期披露的信息不存在需要更正、补充之处。 1、公司前期披露的 ...

浙江亚太药业股份有限公司（证券代码：002370）公告称，公司股票于2025年7月25日、28日、29日连 续三个交易日收盘价格涨幅偏离值累计超过20%，触及深圳证券交易所股票交易异常波动标准。公司核 实确认，前期披露信息无需更正或补充，近期未出现可能影响股价的未公开重大信息，经营情况及内外 部环境未发生重大变化；公司、控股股东及实控人不存在应披露未披露重大事项，且异常波动期间控股 股东及实控人未买卖公司股票。 ...

今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | CRO概念 | 4.00 | 猪肉 | -1.35 | | 重组蛋白 | 2.90 | 养鸡 | -1.12 | | 创新药 | 2.79 | 草甘膦 | -1.10 | | 减肥药 | 2.76 | 粮食概念 | -1.00 | | F5G概念 | 2.43 | 芬太尼 | -0.88 | | 细胞免疫治疗 | 2.42 | PEEK材料 | -0.85 | | 仿制药一致性评价 | 2.30 | 预制菜 | -0.85 | | 共封装光学(CPO) | 2.23 | 生态农业 | -0.78 | | 特钢概念 | 2.08 | C2M概念 | -0.78 | | 先进封装 | 1.91 | 人造肉 | -0.76 | 截至7月29日收盘，仿制药一致性评价概念上涨2.30%，位居概念板块涨幅第7，板块内，104股上涨， 亚太药业、九洲药业、辰欣药业等涨停，南新制药、苑东生物、海特生物等涨幅居前，分别上涨 17.01%、15.45%、15.28%。跌幅居前的有昂 ...

Core Viewpoint - The chemical pharmaceutical sector experienced a significant increase of 2.47% on July 29, with Nanjing Pharmaceutical leading the gains [1] Group 1: Market Performance - The Shanghai Composite Index closed at 3609.71, up 0.33% [1] - The Shenzhen Component Index closed at 11289.41, up 0.64% [1] Group 2: Individual Stock Performance - Nanjing Pharmaceutical (681899) closed at 11.90, with a rise of 17.01% and a trading volume of 388,700 shares, totaling a transaction value of 417 million yuan [1] - Yuandong Biological (688513) closed at 65.92, up 15.45%, with a trading volume of 74,200 shares and a transaction value of 466 million yuan [1] - Microchip Biotech (688321) closed at 38.37, increasing by 12.85%, with a trading volume of 401,800 shares and a transaction value of 1.49 billion yuan [1] - Aoxiang Pharmaceutical (603229) closed at 10.54, up 10.02%, with a trading volume of 480,600 shares and a transaction value of 493 million yuan [1] - Asia-Pacific Pharmaceutical (002370) closed at 6.81, also up 10.02%, with a trading volume of 1,937,200 shares and a transaction value of 1.285 billion yuan [1] - Chenxin Pharmaceutical (603367) closed at 25.93, up 10.01%, with a trading volume of 160,000 shares and a transaction value of 413 million yuan [1] - Fuyuan Pharmaceutical (6801089) closed at 22.90, increasing by 9.99%, with a trading volume of 176,900 shares and a transaction value of 389 million yuan [1] - Nikan Pharmaceutical (688658) closed at 33.02, up 9.96%, with a trading volume of 118,700 shares and a transaction value of 376 million yuan [1] - Luoxin Pharmaceutical (002793) closed at 5.97, increasing by 9.94%, with a trading volume of 421,300 shares and a transaction value of 240 million yuan [1] - Frontier Biotech (688221) closed at 22.42, up 9.74%, with a trading volume of 471,400 shares and a transaction value of 1.023 billion yuan [1] Group 3: Capital Flow - The chemical pharmaceutical sector saw a net inflow of 1.295 billion yuan from main funds, while retail funds experienced a net outflow of 1.198 billion yuan [1] - Speculative funds recorded a net outflow of 97.108 million yuan [1]

Group 1 - The market saw a total of 31 stocks hitting the daily limit up, with a success rate of 63% for limit up attempts [1] - Xizang Tourism became a market focus, achieving a consecutive limit up for 7 trading days, making it a representative high-limit stock [1] - Innovative drug concept stocks showed strong performance, with Apac Pharmaceutical achieving 5 limit ups in 10 trading days due to improved earnings expectations from a subsidiary sale [1] Group 2 - The overall market performance indicated a slight decline in the Shanghai Composite Index by 0.08% and Shenzhen Component Index by 0.04%, while the ChiNext Index rose by 0.92% [1] - The total trading volume in the three major markets reached 11,460.26 billion yuan, with 3,901 stocks declining and 1,468 stocks rising [1] - The chemical pharmaceutical sector attracted the highest net inflow of funds at 1.568 billion yuan, followed by the biopharmaceutical sector with 1.245 billion yuan [1] Group 3 - Other stocks that hit the limit up included Xingfu Blue Ocean, Kejingyuan, and Haichang New Materials, with some ChiNext stocks achieving a 20% limit up, indicating strong market enthusiasm for related concepts [2] - Medical research outsourcing institutions (CRO) and contract development manufacturing organizations (CDMO) were among the top-performing sectors, along with FPGA chips and CXO medical outsourcing [2]

Core Viewpoint - The increasing number of individuals banned from the securities market in China reflects a tightening regulatory environment, with a notable rise in enforcement actions against market manipulation and financial fraud [1][7]. Group 1: Market Bans and Statistics - As of May 30, 2021, a total of 24 individuals have been banned from the securities market in China this year, a significant increase of over 40% compared to 17 individuals banned during the same period last year [2][7]. - Notable cases include Chen Jianming, the actual controller of ST Zhongchang, who was banned for manipulating the company's stock through 101 accounts, resulting in illegal profits of 11.47 million yuan [2][5]. Group 2: Types of Violations - The violations leading to market bans primarily fall into three categories: failure to disclose significant company matters, false or misleading information disclosures, and market manipulation [4][5]. - Specific cases include *ST Jinzheng and other companies where executives were banned for failing to disclose major issues and engaging in fraudulent activities [3][4]. Group 3: Regulatory Environment - The China Securities Regulatory Commission (CSRC) has emphasized a stricter approach to combating fraudulent activities, including financial fraud and market manipulation, with plans to enhance regulatory measures [6][7]. - The CSRC is also in the process of revising the Securities Market Ban Regulations to include new categories of bans and expand the scope of individuals subject to these bans [7][8].

Group 1 - The hepatitis concept sector experienced a short-term surge, with Kewah Bio (002022) hitting the daily limit up [1] - Other companies such as Qianyuan Pharmaceutical (300254), Hendi Pharmaceutical (301211), Da'an Gene (002030), Asia-Pacific Pharmaceutical (002370), and Kangzhi Pharmaceutical (300086) also saw significant increases in their stock prices [1]

Group 1 - The core viewpoint of the articles highlights the increasing activity in the innovative drug sector, driven by favorable government policies and the introduction of a commercial health insurance directory for innovative drugs [1][2] - Since 2025, the government has proposed multiple policies to optimize drug procurement and support innovative drugs, indicating a positive policy environment for the pharmaceutical industry [1] - The 11th batch of national drug procurement is underway, with expectations for optimized rules and price reductions, moving away from a focus on minimum pricing to a more quality-controlled approach [1] Group 2 - Ever since the 14th Five-Year Plan, a total of 402 new drugs have been included in the medical insurance directory, with innovative drug spending projected to reach 3.9 times that of 2020 by 2024, reflecting a 40% annual growth rate [2] - The establishment of a commercial health insurance directory for innovative drugs will provide a supplementary payment channel for drugs not included in the national medical insurance directory, with over 100 drugs already submitted for approval [2] - The precise adjustment of medical insurance policies is reshaping the pharmaceutical industry ecosystem, transitioning from price wars to value wars, and clearing out low-quality production capacity to create market space for high-quality enterprises [2]

Market Overview - As of July 23, the Shanghai Composite Index closed at 3582.30 points, with a slight increase of 0.44 points, representing a change of 0.01% [1] - The Shenzhen Component Index closed at 11059.04 points, down by 40.79 points, a decrease of 0.37% [1] - The ChiNext Index closed at 2310.67 points, with a minor decline of 0.19 points, or 0.01% [1] Trading Activity - A total of 101 A-shares had a turnover rate exceeding 20% on this day, indicating significant trading activity [1] - Notably, C Shanda and C Jiyuan had turnover rates above 50%, with 82.89% and 80.75% respectively, indicating a high level of liquidity and interest in these stocks [1] Top Stocks by Turnover Rate - C Shanda (301609) closed at 66.85 CNY, with a turnover rate of 82.89% and a remarkable increase of 356.00% [1] - C Jiyuan (603262) closed at 40.75 CNY, with a turnover rate of 80.75% and a significant rise of 274.54% [1] - Other notable stocks with high turnover rates include: - Guanlong Energy (301151) at 24.11 CNY, turnover rate of 72.29%, down by 5.67% [1] - Weiman Sealing (301161) at 29.81 CNY, turnover rate of 66.12%, down by 16.05% [1] - Southern Road Machinery (603280) at 34.75 CNY, turnover rate of 64.76%, up by 10.00% [1] Additional Noteworthy Stocks - Other stocks with notable trading activity include: - Sichuan Jinding (600678) at 11.15 CNY, turnover rate of 51.91%, down by 4.21% [1] - Baijia Technology (835857) at 9.56 CNY, turnover rate of 47.74%, up by 17.16% [1] - Jindun Co. (300411) at 15.77 CNY, turnover rate of 43.27%, down by 1.93% [1]

New Stock Issuance - New stock issued by Dingjia Precision at a price of 11.16 on July 22, 2025[1] - ST Kelly's tender offer period is from July 17 to August 15, 2025[1] - ST Zitian and other companies have also announced new stock issuances[1] Market Alerts - Significant abnormal fluctuations reported for several stocks including Guangshengtang and Huayin Power[1] - Multiple companies have disclosed announcements regarding stock performance and market activities[1] - The report includes links to detailed announcements for various stocks, indicating ongoing market monitoring[1]